BrightSpring Health price target raised to $46 from $40 at BMO Capital

BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $46 from $40 and keeps an Outperform rating on the shares. The firm’s deep-dive analysis highlights the strength of BrightSpring’s pharma relationships and competitive positioning, increasing its conviction in the durability of the growth trajectory in its specialty business, the analyst tells investors in a research note. The main catalyst behind the stock’s strong performance has been accelerating growth in its specialty business, the firm added.